Emyria has secured a locally-available supply of patient-ready MDMA thanks to a huge effort from our team and the support of the Australian National University and Mind Medicine Australia.

This supply allows us to initiate dosing with our first patients on our ethics-approved clinical trial while we wait for our larger shipment from Canada pending approval from Health Canada (in progress).

Emyria is evaluating MDMA-assisted therapy ('MDMA-AT') for Post-Traumatic Stress Disorder ('PTSD') in an Australian context. PTSD affects around 1M Australians and MDMA-AT is showing remarkable promising in multiple Phase 3 clinical trials.

The great opportunity - that Emyria is uniquely prepared for - is to demonstrate feasibility and cost-effectiveness of this treatment in an Australian context so we can make it available, safely, to qualified Australians.

Then, the future will be innovation in delivery models and new drugs that build on MDMA's qualities.

Emyria is deeply involved in both care delivery AND drug development so we feel we're uniquely prepared to lead this new frontier.